THE GREY AREA BETWEEN PAIN & ADDICTION EVLOLVING STRATEGIES

Dr. Joel Bordman FMF, 2015



Disclosure of Commercial Support

- This program has received financial support from the following sponsors in the form of an educational grant:
- N/A

Potential for conflict(s) of interest:

- Dr. Bordman has received funding from Purdue, Invidior and Astra Zeneca for consultation service and speaker's bureau
- Indivior produces and distributes a product that will be discussed in this program: Suboxone (Buprenorphine/Naloxone)



Faculty/Presenter Disclosure

- Faculty: Dr. Bordman
- Relationships with commercial interests:
 - Grants/Research Support: N/A
 - Speaker's Bureau: Purdue, Invidior
 - Consultant: Purdue, Invidior, Astra Zeneca



Mitigating Potential Bias

 The Planning Committee has reviewed the presenters' slides and ensured that they are unbiased and free of any inappropriate influence from industry.



Objectives

- review the differential diagnosis of addictive behavior in a chronic pain patient.
- explore treatment options for the patient with addictive behavior and chronic pain.
- to increased comfort in dealing with possible addiction in the chronic pain patient.



After this session participants will be able to:

- Formulate the differential diagnosis of aberrant opioid behaviours in patients with chronic pain
- Communicate effectively with patients when a diagnosis of addiction is being considered

3. Provide ongoing support to patients who require a referral for addiction treatment.

Before we start...

- Is there an issue with opioids in your community?
 - Excessive prescribing?
 - Illegal consumption (including Heroin)?
 - Diversion?
 - Pharmacy irregularities?





"Seriously babe, I can prescribe anything I want"



A common question:

Is it pain or addiction?



A Better Question:

- For Someone on opioids:
 Are they winning their battle against chronic pain? Or....
- Do the risks outweigh the benefits to continuing opioid therapy?

Differential Diagnosis of Someone on opioids who is not winning their battle against chronic pain.

Addiction (4 C's) Criminal Intent (diversion)



DSM-V Substance Use and Addictive Disorders

- Mild 2-3
- Moderate 4-5
- Severe 6–11

*has to cause clinically significant impairment / distress



DSM-V Substance Use and Addictive Disorders

- Unsuccessful attempt to cut down
- Long periods spent obtaining drug or recovering
- Neglecting other life activities
- Use despite ongoing health consequences
- craving

- Consequences of use
- Repeated use in hazardous situations
- Repeated use despite interpersonal harm
- Tolerance
- Withdrawal
- Use for longer than was intended

Source Where Pain Relievers Were Obtained From for Most Recent Nonmedical Use (NSDUH)



- From Friend or Relative for Free
- From One Doctor
- Bought from Friend or Relative
- Took from Friend or Relative without Asking
- Bought from Drug Dealer or Other Stranger
- Some Other Way
- From More Than One Doctor
- Bought on the Internet

rescription and from Doctor's Office/Clinic/Hospital/Pharmacy" and "some other way" th Statistics and Que. A structure of Applied Studies), National Survey on Drug Use and Health, 2010-2011

Other includes sources "wrote fake prescription, SAMHSA, Center for Behavioral Health Statistics and O Differential Diagnosis of Someone on opioids who is not winning their battle against chronic pain.

- Addiction (4 C's)
- Criminal Intent (diversion)
- Pseudo-addiction (inadequate analgesia)

15

- Opioid Induced Hyperalgesia
- Opioid unresponsiveness
- Other psychiatric diagnosis

Other psychiatric diagnosis

- Organic Mental Syndrome (confused)
- Personality Disorder (impulsive, entitled)
 - Cluster B: Narcissistic, hystrionic, borderline
- Chemical Coping (drug overly central)
- Self medicate for:
 - Depression
 - Anxiety

- PTSD
- Situational stressors

Pain treatment 2015

Primum non nocere First, do no harm



PEARL...

- If someone is displaying signs of addiction, the biggest way we can HELP them, is to accept this as a possible diagnosis and explore treatments
- In addition, remember that DENIAL and AMBIVALENCE TO TREATMENT are a part of the illness



Complex problems rarely have simple solutions.

TREATMENT

Physical / Rehabilitative



Medical

- · Pharmacological
- Interventional

Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guidelines

www.camh.net

Principle author: Dr. Curtis Handford October, 2011



Buprenorphine/Naloxone Indication

- Buprenorphine/Naloxone is indicated for the substitution treatment of opioid dependence in adults
- Suggested training:

www.suboxonecme.ca

www.camh.net (Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guidelines)

It should NOT be used as part of a opioid rotation in patients without opioid dependence

BuTrans[®]: Specific Features

BuTrans[®]...

Is specifically indicated for persistent moderate pain lasting an extended period

due Pharma Canada. BuTrans[®] Product Monograph, July 2010.

How is buprenorphine different than other opioids?

Terminology

- AGONIST
 - A ligand the binds to the brain receptor and activates cellular signaling

ANTAGONIST

 A ligand the binds to a brain receptor and blocks other ligands from binding; it does not activate any cellular signaling

PARTIAL AGONIST

 A ligand that binds to a brain receptor and activates cellular signaling, but only at a fraction of that receptors capacity to signal

A confusing combination

Buprenorphine Partial mu agonist Kappa antagonist Naloxone

Mu antagonist

HOW IT WORKS

Combines buprenorphine and naloxone in one pill.



Acts like buprenorphine alone.

When taken under the tongue, as directed, the naloxone is silent... it has no effect.



Naloxone will cause withdrawal symptoms for opioid-dependent people who have heroin or methadone (full agonists) in their bodies at the time of injection.

BUPRENORPHINE: A "SAFE CEILING"

- Unlike full agonists, agonist effects of buprenorphine reach a ceiling¹
- Less likely to cause respiratory depression in overdose
 - Ceiling can be compromised by concomitant alcohol or

other central nervous system depressants, or when buprenorphine is misused²





Safety

 Diversion: Patients who use methadone nonmedically have higher hospitalization rates, greater ICU utilization rates, and considerably worse medical outcomes when compared with patients who use buprenorphine nonmedically

Lee S, Medical outcomes associated with nonmedical use of methodone and buprenorphine, J Emerg Med 2013

Pain Medicine 2014

- Conversion from high dose full opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients
- Daitch, et al



Daitch, et al

- Subjects:
 - 35 chronic pain patients (age 24-66)
 - MEDD 200–1370mg (mean 550mg)
 - Average buprenorphine dose 28mg
- Methods:
 - Retrospective chart analysis QoL scores and numerical pain levels
 - 2 months



Daitch, et al

- Results:
 - Mean pain scores decreased at 2 months from 7.2 to 3.5
 - QoL scores improved from 6.1 to 7.1



THANK YOU

